Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very strong margins and returns
About
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Target Price
The average target price of CORT is 121 and suggests 44% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell